arrow
R

Robert R. Jenq

The University of Texas MD Anderson Cancer Center
H指数:61
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant

移植物抗宿主病预防措施塑造造血细胞移植后的T细胞生物学和免疫重建

2026-10-210
PRE
Sugar-rich foods exacerbate antibiotic-induced microbiome disruption

高糖食物加剧抗生素诱导的微生物组紊乱

Nature
IF48.5
2026-09-300
OAAI
Inclusion of Multi-Omic Biomarkers Improves Prediction Accuracy of Response, Relapse, and Overall Survival in Acute Myeloid Leukemia Patients Receiving High-Intensity Induction Chemotherapy

多组学生物标志物的纳入提高了接受高强度诱导化疗的急性髓系白血病患者的治疗反应、复发和总生存期的预测准确性

2026-09-170
OAAI
MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo

MaaT013粪便微生物疗法在体内外调节与GvHD发病机制相关的关键胃肠和免疫过程

2026-09-150
OA
Microbial signals in primary and metastatic brain tumors

原发性和转移性脑肿瘤中的微生物信号

2025-11-140
OAAI
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer

炎症和突变负担与nivolumab或ipilimumab联合疗法的疗效在结直肠癌中存在差异关联。

2025-10-060
OAAI
Inflammatory markers and microbiome dysbiosis in hematopoietic cell transplant recipients with lung graft-versus-host disease

炎症标志物和微生物组失调在发生肺部移植物抗宿主病的造血细胞移植受者中的研究

2025-06-010
PRE
Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective Study

免疫效应细胞治疗后针对白喉、破伤风和肺炎球菌的体液免疫和抗体反应: 一项前瞻性研究

2024-09-190
OAAI
Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism

细菌联盟在代谢功能障碍相关的脂肪性肝炎中对纤维化的保护作用以及氨基酸代谢的作用

2024-09-060
OAAI